Update in the medical therapy of Cushing's disease

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 20, Issue 4, 2013, Pages 330-334

  Nieman, Lynnette K ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

cabergoline; Cushing's disease; mifepristone; pasireotide

Indexed keywords

ANTIHYPERTENSIVE AGENT; BROMOCRIPTINE; CABERGOLINE; CORTICOTROPIN; DOPAMINE; DOPAMINE 2 RECEPTOR; HYDROCORTISONE; KETOCONAZOLE; MIFEPRISTONE; PASIREOTIDE; PROGESTERONE; RETINOIC ACID; SOMATOSTATIN; TRANSCRIPTION FACTOR;

ACTH SECRETING CELL; ADRENAL INSUFFICIENCY; ADRENALECTOMY; AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ASTHENIA; CHOLELITHIASIS; CLINICAL FEATURE; CORTICOTROPIN RELEASE; CUSHING DISEASE; CUSHINGOID SYNDROME; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; FATIGUE; GLUCOSE INTOLERANCE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCORTISOLISM; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; MONOTHERAPY; NAUSEA; PROGESTERONE BLOOD LEVEL; REVIEW; SIDE EFFECT; TRANSSPHENOIDAL SURGERY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; XEROSTOMIA;

DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; ERGOLINES; HUMANS; HYDROCORTISONE; PITUITARY ACTH HYPERSECRETION; SOMATOSTATIN;

EID: 84880317250     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e3283631809     Document Type: Review

References (21)

1. Tritos NA, Biller BM, Swearingen B. Medscape, Management of Cushing disease. Nat Rev Endocrinol 2011; 7:279-289.
2. Pivonello R, Ferone D, de Herder WW, et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 2004; 89:2452-2462.
3. Pivonello R, De Martino MC, Cappabianca P, et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 2009; 94:223-230.
4. Godbout A, Manavela M, Danilowicz K, et al. Cabergoline monotherapy in the long-term treatment of Cushing's disease. Eur J Endocrinol 2010; 163:709-716.
5. Manavela MP, Danilowicz K, Bruno OD. Macrocorticotropinoma shrinkage and control of hypercortisolism under long-term cabergoline therapy: case report. Pituitary 2012; 15 (Suppl 1):33-36.
6. Vilar L, Naves LA, Azevedo MF, et al. Effectiveness of cabergoline in mono-therapy and combined with ketoconazole in the management of Cushing's disease. Pituitary 2010; 13:123-129.
7. Barbot M, Albiger N, Ceccato F, et al. Combination therapy for Cushing's disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole? Pituitary 2013. [Epub ahead of print]. PMID 23468128.
8. Ferone D, Gatto F, Arvigo M, et al. The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. J Mol Endocrinol 2009; 42:361-370.
9. Hofland LJ, van der Hoek J, Feelders R, et al. The multiligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 2005; 152:645-654.
10. Colao A, Petersenn S, Newell-Price J, et al., Pasireotide B2305 Study Group. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med 2012; 366:914-924
11. FDA Advisory committee report. http://www.fda.gov/downloads/Advisory- Committees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMeta bolicDrugsAdvisoryCommittee/UCM326811.pdf, 2012, verified 4/1/2013.
12. European Medicines Agency (EMA). European Public Assessment Report. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment- report/human/002052/WC500128058.pdf, 2012, verified 4/1/2013.
13. Katznelson L. Sustained improvements in plasma ACTH and clinical status in a patient with Nelson's syndrome treated with pasireotide LAR, a multi-receptor somatostatin analog. J Clin Endocrinol Metab 2013; 98:1803-1807.
14. Feelders RA, de Bruin C, Pereira AM, et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med 2010; 362:1846-1848.
15. Páez-Pereda M, Kovalovsky D, Hopfner U, et al. Retinoic acid prevents experimental Cushing syndrome. J Clin Invest 2001; 108: 1123-1131.
16. Castillo V, Giacomini D, Páez-Pereda M, et al. Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology 2006; 147:4438-4444.
17. Pecori Giraldi F, Ambrogio AG, Andrioli M, et al. Potential role for retinoic acid in patients with Cushing's disease. J Clin Endocrinol Metab 2012; 97:3577-3583.
18. Nieman LK, Chrousos GP, Kellner C, et al. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. JClin Endocrinol Metab 1985; 61:536-540.
19. Fleseriu M, Biller BM, Findling JW, et al. SEISMIC Study Investigators. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab 2012; 97:2039-2049.
20. Jang GR, Benet LZ. Antiprogestin pharmacodynamics, pharmacokinetics, and metabolism: implications for their long-term use. J Pharmacokinet Biopharm 1997; 25:647-672.
21. Dekkers OM, Horváth-Puhó E, Jørgensen JO, et al. Multisystem morbidity and mortality in Cushing's syndrome: a cohort study. J Clin Endocrinol Metab 2013. [Epub ahead of print]. PMID 23533241.